MedTrace Logo

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

NCT06083688 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2025-11-19

No results posted yet for this study

Summary

This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ). Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.

Conditions

  • Malaria,Falciparum
  • Anemia in Children

Interventions

DRUG

Dihydroartemisinin-Piperaquine

Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).

DRUG

Chloroquine

Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.

DRUG

Sulfadoxine-pyrimethamine-amodiaquine

Treatment in Arm 2 (females less than 13 years old and all males).

Sponsors & Collaborators

  • Kamuzu University of Health Sciences

    collaborator OTHER

  • Liverpool School of Tropical Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2025-07-31
Completion
2026-01-31

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083688 on ClinicalTrials.gov